---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-042879"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T17:01:16.810026+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics Q2 net loss $15.2M; cash $168.1M; Takeda accelerates UC program

## Summary
- Net loss $15.2M vs $8.3M YoY; R&D expense $14.0M, G&A $5.9M.
- Cash and equivalents $168.1M at June 30, 2021, expected to fund operations into mid-2023.
- Takeda elected to accelerate leadership of FIN-524/TAK-524 ulcerative colitis program.
- CP101 open-label PRISM-EXT topline data from >130 patients expected H2 2021.
- Topline data from FIN-211 in ASD and CP101 in chronic HBV expected H2 2022.

## SEC filing metadata
- accession: 0001564590-21-042879
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000156459021042879/0001564590-21-042879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000156459021042879/fnch-8k_20210810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-042879
- JSON: https://secwatch.observer/filing/0001564590-21-042879.json
- Plain text: https://secwatch.observer/filing/0001564590-21-042879.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.